ACADIA Pharmaceuticals Inc. News
Acadia Stock Falls on Morgan Stanley Downgrade, Price Target Cut
Acadia Pharmaceuticals shares slumped lower Thursday as Morgan Stanley says it it unclear what will drive stock appreciation in the next year.
Cramer's Mad Money Recap: Brunswick, Clorox, Logitech
Another heavy week of financial reports is on tap and Jim Cramer's got the details on who and what to watch for.
Premarket Movers Tuesday - Illumina, ViacomCBS, Snap, Acadia
Stocks moving in premarket trading Tuesday include Illumina, Duck Creek Technologies, ViacomCBS, Snap and Acadia Pharmaceuticals.
Acadia Slides as FDA Rejects Expanded Use of Nuplazid
Acadia says it will immediately request a meeting to work with the FDA regarding the agency's concerns.
Weekly Upgrades and Downgrades: Peloton, Bumble, Tesla
TheStreet's weekly guide to upgrades, downgrades and price-target changes includes Peloton, Tesla and AMC Entertainment.
Acadia Analysts Cut Targets as FDA Sees Application Deficiencies
A new-drug application for Acadia's psychosis treatment was paused by the FDA due to deficiencies that the agency didn't specify.
Premarket Movers Tuesday - Second Sight, Acadia Pharma, Tesla
Stocks moving in premarket trading on Tuesday include Second Sight, Acadia Pharma, GameStop and Tesla.
Individual Investors Are Back: Cramer's 'Mad Money' Recap (Monday 12/7/20)
Jim Cramer salutes the new generation of investors as independent and optimistic.
Acadia Depression Drug Misses Key Endpoint in Phase III Trial
Acadia Pharma shares fell after the biopharma said a trial of a depression drug “didn’t achieve statistical significance on the primary endpoint.”
Best Stocks of the Decade: Acadia’s Drug Development Success
San Diego biopharma’s spectacular stock gains since 2010 have been driven by its development of Nuplazid, a drug to treat Parkinson’s disease psychosis.
Tesla Chart Faces Key Hurdle. Here's What Happens If It Fails.
Tesla stock faces a key hurdle on the charts. Here's what happens if resistance rejects it.
Tim Cook and Apple Make a Move That Could Annoy China
iPhone maker wants to diversify its supply chain and expand in a crucial market.